Pros | - | ![]() 3Y returns in the top 25% of the category. ![]() Larger AUM within category. | ||
Cons | - | - |
INDMoney rank | - | - | ||
Category,Subcateogry | Equity,Index Funds | Equity,Index Funds | ||
Fund Age | 2 Years | 4 Years | ||
Fund Size | 95 Cr | 8199 Cr | ||
Min Investment | SIP ₹1000 Lumpsum ₹1000 | SIP ₹500 Lumpsum ₹1000 | ||
Expense Ratio | 0.37% | 0.43% | ||
Exit Load | 0% | 0% | ||
Benchmark Index | Nifty Pharma TR INR | Nifty200 Momentum 30 TR INR |
No of Holdings | 22 | 31 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (22.49%) Cipla Ltd (10.69%) Divi's Laboratories Ltd (10.24%) Dr Reddy's Laboratories Ltd (9.45%) Lupin Ltd (5.7%) | InterGlobe Aviation Ltd (5.42%) ICICI Bank Ltd (5.38%) HDFC Bank Ltd (5.27%) SBI Life Insurance Co Ltd (5.14%) Bharti Airtel Ltd (5.04%) | ||
No of Sectors | 1 | 8 | ||
Top 3 Sectors | Health (100%) | Financial Services (49.29%) Industrial (15.06%) Tech (9.37%) | ||
Equity % | 99.8% | 99.9% | ||
Debt % | - | - | ||
P/E | 32.3 | 39.06 | ||
P/B | 4.94 | 6.84 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -1.11% | -0.45% | ||
3-Month Return | 2.87% | -2.04% | ||
6-Month Return | 10.83% | 12.62% | ||
1-Year Return | -5.26% | -17.71% | ||
3-Year Return | - | 16.39% | ||
5-Year Return | - | - |
Sharpe | - | 0.55 | ||
Alpha | - | -0.17 | ||
Beta | - | 1 | ||
Standard Deviation | - | 17.84 | ||
Information Ratio | - | -1.05 |
Description | ICICI Prudential Nifty Pharma Index Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | UTI Nifty200 Momentum 30 Index Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Ashwini Shinde,Nishit Patel | Ayush Jain,Sharwan Kumar Goyal |